Aelis Farma SA (EPA:AELIS)

Market Cap	13.60M -16.6%
Revenue (ttm)	2.08M -62.5%
Net Income	-6.43M
EPS	-0.47
Shares Out	13.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,687
Open	1.014
Previous Close	1.014
Day's Range	1.000 - 1.020
52-Week Range	0.950 - 2.300
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About Aelis Farma

Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome; and CB1-SSi, a new molecular entities to treat oth...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 16
• Stock Exchange: Euronext Paris
• Ticker Symbol: AELIS

Financial Performance

In 2025, Aelis Farma's revenue was 2.08 million, a decrease of -62.53% compared to the previous year's 5.56 million. Losses were -6.43 million, -13.71% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error